Circulating miR-221/222 expression as microRNA biomarker predicting tamoxifen treatment outcome: a case-control study

CONCLUSION: The use of circulating miR-221/222 expression can predict relapse as well as resistance to tamoxifen treatment in BC patients, and their testing is recommended for luminal subtype BC patients who will undergo tamoxifen therapy to determine their risk of tamoxifen resistance early, increasing treatment effectiveness.PMID:37554919 | PMC:PMC10406100 | DOI:10.1097/MS9.0000000000001061

Source: Cancer Control - August 9, 2023 Category: Cancer & Oncology Authors: Ilhamjaya Patellongi Alfiah Amiruddin Muhammad N Massi Andi A Islam Muhammad Y Pratama Noorwati Sutandyo Nani H M Latar Muhammad Faruk Source Type: research